PRESS RELEASES

PRESS RELEASES

Date Title and Summary Additional Formats
Toggle Summary OpGen Reports Fourth Quarter and Full Year 2017 Financial Results and Provides a Business Update
Acuitas® AMR Gene Panel u5.47 introduced for Research Use Only Fourth quarter revenue consistent with previous year; net loss decreases 38% year over year Conference call begins at 4:30 p.m. Eastern time today GAITHERSBURG, Md. , March 15, 2018 (GLOBE NEWSWIRE) -- OpGen, Inc.
View HTML
Toggle Summary OpGen Announces Collaborator in Verification Study for Acuitas® Test
Study to evaluate potential utility in management of complicated urinary tract infections GAITHERSBURG, Md. , March 13, 2018 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) announced today that it is collaborating with Beth Israel Deaconess Medical Center (BIDMC) in Boston on a verification study for
View HTML
Toggle Summary OpGen Announces Date of Fourth Quarter and Fiscal Year 2017 Financial Results Conference Call
GAITHERSBURG, Md. , March 05, 2018 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) announced today that the Company will report its fourth quarter and fiscal year 2017 financial results after close of market on Thursday, March 15, 2018 . OpGen’s management team will host a live conference call and
View HTML
Toggle Summary OpGen to Present at the Cowen and Company 38th Annual Health Care Conference
GAITHERSBURG, Md. , March 01, 2018 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) announced today that Evan Jones , Chairman and Chief Executive Officer of the Company, will present a corporate overview at the Cowen and Company 38th Annual Health Care Conference on Tuesday, March 13, 2018 at 8:40
View HTML
Toggle Summary OpGen Strengthens Supplier Relationship to Use Industry-Leading Real-Time PCR Technology for New Acuitas® Tests
Test rapidly detects 47 antimicrobial resistance markers directly from urine and bacterial isolates GAITHERSBURG, Md. , Feb. 13, 2018 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) announced today that it has entered into a global supply agreement to use Thermo Fisher Scientific’s real-time PCR
View HTML
Toggle Summary OpGen Announces Closing of $12 Million Public Offering
GAITHERSBURG, Md. , Feb. 07, 2018 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) announces the closing of its previously announced public offering of 2,841,152   units at $3.25 per unit and 851,155 pre-funded units at $3.24 per pre-funded unit, raising gross proceeds of approximately $12 million .
View HTML
Toggle Summary OpGen Regains Compliance With Nasdaq Listing Requirements
GAITHERSBURG, Md. , Feb. 05, 2018 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) announces that it has received notification from Nasdaq that the minimum bid price deficiency of the Company’s stock has been cured, and it will continue to be listed and traded on The Nasdaq Stock Market .  In
View HTML
Toggle Summary OpGen Announces Pricing of $12 Million Upsized Public Offering
GAITHERSBURG, Md. , Feb. 02, 2018 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) announces the pricing of a public offering of an aggregate of 3,692,307 units. Each unit is comprised of one share of common stock (or common stock equivalent) and one common warrant to purchase one-half of a share of
View HTML
Toggle Summary OpGen Introduces New RUO Rapid Test for Infection Control and Surveillance Studies
GAITHERSBURG, Md. , Feb. 01, 2018 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) announced today that it has introduced a Research Use Only (RUO) Acuitas® AMR Gene Panel u5.47 test for commercial sale. The Acuitas AMR Gene Panel u5.47 test was developed to detect the most common bacterial causes of
View HTML
Toggle Summary OpGen Announces Execution of Reverse Stock Split
GAITHERSBURG, Md. , Jan. 17, 2018 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) announced today that it will implement a 1-for-25 reverse stock split of its common stock. The Company filed an amendment to its Certificate of Incorporation to effect the reverse stock split on January 17 , 2018.  The
View HTML